Published in Drug Law Weekly, December 7th, 2004
The financing was led by Newport Partners and involved a syndicate of private and institutional investors, including the Canadian Medical Discoveries Fund.
The transaction also included an investment by Transition Therapeutics, Inc., a Canadian biotech company. Along with Transition's investment, ENI will also have access to the drug-development, intellectual property, and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.